Ashland reports third quarter 2026 results and reaffirms full-year sales & Adjusted EBITDA outlook

* Sales of $497 million, up seven percent from the prior-year quarter * Income from continuing operations of $41 million, or $0.89 per diluted share * Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $47 million, or $1.02 per diluted share * Net income of $16 million, or $0.35 per diluted share * Sales volumes rose six percent from the prior-year quarter, with gains achieved across all business units * Adjusted EBITDA of $109 million, down four percent from the prior-year quarter, primarily reflecting growth in Life Sciences and Personal Care, more than offset by lower Specialty Additives and Intermediates earnings * Cash flows provided by operating activities of $121 million; Ongoing Free Cash Flow(2) of $103 million * Reaffirming full‑year fiscal 2026 sales guidance of $1,835-$1,870 million and Adjusted EBITDA guidance of $385-$400 million WILMINGTON, Del., July 28, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results(1) for the third quarter of fiscal year 2026, which ended June 30, 2026, and reaffirmed its full-year fiscal 2026 sales and Adjusted EBITDA outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.